• ce daily in the RA programme (0.24 (0.13-0.41)).

    To characterise the safety and tolerability of nintedanib and the dose adjustments used to manage adverse events in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

    In the SENSCIS trial, patients with SSc-ILD were randomised to receive nintedanib 150 mg t…[Read more]

  • TGFβ-SMAD3 signaling is a major driving force for cancer metastasis, while BMP-SMAD1/5 signaling can counteract this response. Analysis of gene expression profiles revealed that an increased TGFβ-SMAD3 and a reduced BMP-SMAD1/5 targeted gene expression signature correlated with shortened distant metastasis free survival and overall survival of p…[Read more]

  • Moreover, patients with ECOG 0 treated with IC (TPF or PF) followed by CRT had a better TTF than those with CRT alone. There were no statistically significant differences in terms of OS, PFS or TTF, according to the tumor load or affected nodes.

    After a long follow-up, the TTCC 2503 trial failed to show the benefit of IC-CRT in…[Read more]

  • Haas Spears became a registered member 6 months, 3 weeks ago